SB203580 (Adezmapimod) is a highly selective p38 MAPK inhibitor. It affects p38 MAPK and NF-κB signaling pathways by blocking p38 phosphorylation and downstream targets, thereby inhibiting inflammation, oxidative stress, apoptosis, and fibrosis.
SB203580 (Adezmapimod) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for SB203580 (Adezmapimod) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.